title: Clinical islet transplantation at the University of California, San Francisco.
abstract: The UCSF clinical islet transplant program has evolved to utilize immunosuppressive strategies that do not rely on CNIs or other nephro- and beta-cell-toxic immunosuppressive agents. These novel strategies depend on lymphocyte-depleting induction immunotherapy and maintenance immunosuppression with novel agents that focus on co-stimulation and/or lymphocyte migration blockade. These drugs are well tolerated, frequently allow establishment of insulin independence after single islet infusions, and minimize allosensitization. Our early results suggest these regimens will be attractive immunosuppressive agents for future protocols in allogeneic islet transplantation as well as protocols utilizing stem-cell-derived beta cells.
authors.affiliation: Transplant Surgery, University of California San Francisco, San Francisco, CA, USA.
authors.forename: Andrew M
authors.initials: AM
authors.lastname: Posselt
authors.forename: Gregory L
authors.initials: GL
authors.lastname: Szot
authors.forename: Lynda A
authors.initials: LA
authors.lastname: Frassetto
authors.forename: Umesh
authors.initials: U
authors.lastname: Masharani
authors.forename: Peter G
authors.initials: PG
authors.lastname: Stock
mesh_terms: D000046:Academic Medical Centers; D003922:Diabetes Mellitus, Type 1 / Q000601:surgery*; D006084:Graft Rejection / Q000276:immunology / Q000517:prevention & control; D006085:Graft Survival; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007328:Insulin / Q000627:therapeutic use; D016381:Islets of Langerhans Transplantation / Q000009:adverse effects; D016730:Program Development; D015397:Program Evaluation; D012495:San Francisco; D013997:Time Factors; D009927:Tissue and Organ Procurement; D016896:Treatment Outcome
chemical_list: D007004:Hypoglycemic Agents; D007166:Immunosuppressive Agents; D007328:Insulin